Literature DB >> 20922414

Morphological alterations and growth inhibition of Leishmania (L.)amazonensis promastigotes exposed to zidovudine (AZT).

Carolina A Araújo1, Aline A Araújo, Camilla L Batista, Milton A P Oliveira, Valeria Oliveira, Ruy S Lino Junior, Marina C Vinaud, Jose C B Bezerra.   

Abstract

Leishmania parasites cause a worldwide public health disease and its treatment is still based on pentavalent antimonials which present financial and toxicologic limitations. Some nucleosidic derivatives have demonstrated anti-leishmanial properties and this study aims to evaluate the in vitro morphologic alterations and growth inhibition of Leishmania (L.) amazonensis promastigotes exposed to zidovudine at several concentrations. The citotoxicity of zidovudine (AZT) to macrophages was determined by an MTT assay. After which the promastigotes were exposed to concentrations of AZT, ranging from 1 to 50 μM. The evaluation of survival and morphometry alterations were performed in two distinct phases of in vitro growth, on the third and sixth days, representing the logarithmic and stationary phases, respectively. Slides with the promastigotes were photographed and analyzed using Image J. A significant reduction of parasite number in the logarithmic phase of in vitro growth was observed when the parasites were submitted to 20, 30, 40, and 50 μM of AZT. Morphometric alterations were observed such as an increase in width of the body, cytoplasmic granulations and vacuolizations. These data indicate the toxicity of AZT which prevents the parasite's multiplication, indicating a promising use of AZT as an anti-leishmania drug.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20922414     DOI: 10.1007/s00436-010-2096-3

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  15 in total

Review 1.  New antileishmanial candidates and lead compounds.

Authors:  Julian V Richard; Karl A Werbovetz
Journal:  Curr Opin Chem Biol       Date:  2010-04-17       Impact factor: 8.822

2.  Antiviral activity of indole derivatives.

Authors:  Michele Giampieri; Alessandro Balbi; Mauro Mazzei; Paolo La Colla; Cristina Ibba; Roberta Loddo
Journal:  Antiviral Res       Date:  2009-05-13       Impact factor: 5.970

3.  Furazolidone is a selective in vitro candidate against Leishmania (L.) chagasi: an ultrastructural study.

Authors:  Juliana Quero Reimão; Noemi Nosomi Taniwaki; André Gustavo Tempone
Journal:  Parasitol Res       Date:  2010-03-30       Impact factor: 2.289

Review 4.  Drugs targeting mitochondrial functions to control tumor cell growth.

Authors:  Nathalie Dias; Christian Bailly
Journal:  Biochem Pharmacol       Date:  2005-07-01       Impact factor: 5.858

Review 5.  Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis.

Authors:  Hiro Goto; José Angelo Lauletta Lindoso
Journal:  Expert Rev Anti Infect Ther       Date:  2010-04       Impact factor: 5.091

6.  Synthesis and in vitro antileishmanial activity of 5-substituted-2'-deoxyuridine derivatives.

Authors:  Corinne Peyron; Rachid Benhida; Christian Bories; Philippe M Loiseau
Journal:  Bioorg Chem       Date:  2005-09-15       Impact factor: 5.275

7.  Early effects of AZT on mitochondrial functions in the absence of mitochondrial DNA depletion in rat myotubes.

Authors:  O Cazzalini; M C Lazzè; L Iamele; L A Stivala; L Bianchi; P Vaghi; A Cornaglia; A Calligaro; D Curti; A Alessandrini; E Prosperi; V Vannini
Journal:  Biochem Pharmacol       Date:  2001-10-01       Impact factor: 5.858

8.  Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein.

Authors:  Caroline Henrike Storch; Dirk Theile; Heike Lindenmaier; Walter Emil Haefeli; Johanna Weiss
Journal:  Biochem Pharmacol       Date:  2007-01-24       Impact factor: 5.858

9.  Two separate growth phases during the development of Leishmania in sand flies: implications for understanding the life cycle.

Authors:  Sharon M Gossage; Matthew E Rogers; Paul A Bates
Journal:  Int J Parasitol       Date:  2003-09-15       Impact factor: 3.981

10.  Antileishmanial activity and ultrastructural alterations of Leishmania (L.) chagasi treated with the calcium channel blocker nimodipine.

Authors:  André Gustavo Tempone; Noemi Nosomi Taniwaki; Juliana Quero Reimão
Journal:  Parasitol Res       Date:  2009-04-08       Impact factor: 2.289

View more
  3 in total

1.  Antileishmanial activity of antiretroviral drugs combined with miltefosine.

Authors:  Sonya Costa; Marisa Machado; Cláudia Cavadas; Maria do Céu Sousa
Journal:  Parasitol Res       Date:  2016-06-01       Impact factor: 2.289

2.  Structural and Kinetic Characterization of Thymidine Kinase from Leishmania major.

Authors:  Jennifer Timm; Cristina Bosch-Navarrete; Eliseo Recio; Joanne E Nettleship; Heather Rada; Dolores González-Pacanowska; Keith S Wilson
Journal:  PLoS Negl Trop Dis       Date:  2015-05-15

Review 3.  Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.

Authors:  Wim Adriaensen; Thomas P C Dorlo; Guido Vanham; Luc Kestens; Paul M Kaye; Johan van Griensven
Journal:  Front Immunol       Date:  2018-01-12       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.